SYNGENE - IntraDay Trade Analysis with Live Signals

Last Updated Time : 20 Dec 25, 07:03 am

IntraDay Trade Rating: 3.6

📊 Analysis: SYNGENE shows moderate potential for intraday trading today. RSI at 57.3 indicates neutral-to-positive momentum, while MACD (1.83) is slightly positive, suggesting mild bullish sentiment. Current price (655 ₹) is above DMA 50 (644 ₹) but below DMA 200 (672 ₹), reflecting mixed signals. Volume (9,60,566) is higher than weekly average (7,79,202), supporting intraday liquidity.

💡 Optimal Buy Price: 648–652 ₹ (near support zone).

🎯 Profit Exit Levels: 664 ₹ (first resistance), 675 ₹ (secondary resistance).

🛡️ Stop-Loss: 640 ₹ (below near-term support).

⏱️ If Already Holding: Consider exiting near 664–675 ₹ if momentum slows. If price breaks below 640 ₹ with volume, cut losses immediately.

✅ Positive

• 📈 ROCE (12.8%) and ROE (9.78%) show reasonable capital efficiency.
• 💰 Low debt-to-equity (0.07) ensures financial stability.
• 📦 Strong trading volume supports intraday liquidity.
• 🏦 DII holding increased (0.57%), reflecting domestic institutional support.

⚠️ Limitation

• 📉 High P/E (60.3) compared to industry average (46.0).
• 🔻 Quarterly profit variance (-31.5%) shows earnings pressure.
• 📊 PEG ratio (46.8) suggests significant overvaluation relative to growth.

📰 Company Negative News

• ⚠️ FII holding decreased (-0.20%), showing reduced foreign investor confidence.
• 📉 PAT declined (66.2 Cr. vs 74.0 Cr. previous quarter).

🌟 Company Positive News

• 💡 EPS of 10.9 ₹ supports long-term fundamentals.
• 🏭 Market cap of 26,378 Cr. highlights strong industry presence.

🏭 Industry

• 📊 Industry PE at 46.0, lower than SYNGENE’s valuation, indicating premium pricing.
• 🌱 Biotech & pharma sector continues to benefit from R&D demand and healthcare growth trends.

📌 Conclusion

SYNGENE is a moderate intraday candidate today with positive MACD and strong volume, but high valuation and declining profits limit upside. Traders may attempt entries near 648–652 ₹ with profit exits at 664–675 ₹ and stop-loss at 640 ₹. Suitable for cautious intraday trades with momentum confirmation.

Would you like me to extend this into a peer benchmarking overlay against biotech stocks like BIOCON, DIVISLAB, and LAURUSLABS to highlight relative intraday strength?